Table 1.

Clinically Relevant Drugs Reported to Influence DNA Methylaiton

Drug	Therapeutic Class	Clinical Data	Reference(s)
Azacitidine  Decitabine	Nucleoside analogs	Delayed progression time to AML and enhanced hematologic  activity and survival in patients with MDS	101, 102
Hydralazine	Nonnucleoside  analogs	Demethylated and reactivated tumor suppressor genes and,  when used with valproate, improved progression-free  survival in patients with cervical cancer	109, 110
MG98	Antisense  oligonucleotides	Suppressed DNMT1 expression and exhibited some clinical  activity in patients with advanced solid malignances	124

AML, Acute myeloid leukemia; DNMT, DNA methyltransferase; MDS, myelodysplastic syndromes.